The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study

Recruiting Observational Study
Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
10,000 (estimated)
Sponsor
Shanghai Zhongshan Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Male or female over the age of 18; 2. First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria; 3. Understand the purpose and procedure of this t…
Contacts

Peng Liu, PhD, MD

+8621-64041990

liu.peng@zs-hospital.sh.cn

CONTACT

Jing Li, MD

+8621-64041990

li.jing6@zs-hospital.sh.cn

CONTACT